ENMD-2076

• Description:

  ENMD-2076 is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Aurora Kinase; FGFR; FLT3; PDGFR; Src; VEGFR

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage; Epigenetics; Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/enmd-2076.html

• Purity:

  99.99

• Solubility:

  DMSO : ≥ 31 mg/mL

• Smiles:

  CC1=CC(NC2=NC(/C=C/C3=CC=CC=C3)=NC(N4CCN(CC4)C)=C2)=NN1

• Molecular Formula:

  C21H25N7

• Molecular Weight:

  375.47

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Fletcher GC, et al. ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action. Mol Cancer Ther. 2011 Jan;10 (1) :126-37.|[2]Wang X, et al. Preclinical activity of a novel multiple tyrosine kinase and aurora kinase inhibitor, ENMD-2076, against multiple myeloma. Br J Haematol. 2010 Aug;150 (3) :313-25.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• Isoform:

  Aurora A; PDGFRα; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4

• Citation 01:

  Am J Pathol. 2019 Oct;189 (10) :2090-2101.|Int J Gynecol Cancer. 2017 Oct;27 (8) :1666-1674. |Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Am J Pathol. 2019 Oct;189 (10) :2090-2101.

• CAS Number:

  [934353-76-1]